Summary
Thermo Fisher Scientific Inc. (TMO) filed an 8-K report on March 31, 2016, to announce the successful completion of its acquisition of Affymetrix, Inc. This strategic move signifies a significant expansion for Thermo Fisher in the genetic analysis space, aiming to strengthen its position and offerings in the life sciences industry. Investors should note that this acquisition is expected to enhance the company's capabilities and market reach within a key growth area.
Key Highlights
- 1Thermo Fisher Scientific Inc. has completed its acquisition of Affymetrix, Inc.
- 2The acquisition was officially announced via a press release dated March 31, 2016.
- 3This event marks a significant strategic development for Thermo Fisher in the genetic analysis market.
- 4The filing of this 8-K report officially documents the completion of the transaction.
- 5The press release detailing the acquisition is attached as an exhibit to this filing.
Frequently Asked Questions
The main event reported is the completion of Thermo Fisher Scientific Inc.'s acquisition of Affymetrix, Inc.
The acquisition of Affymetrix was completed on or before March 31, 2016, as announced in the press release filed with this 8-K.
The acquisition of Affymetrix is a strategic move expected to enhance Thermo Fisher's capabilities and market position within the genetic analysis and life sciences sectors.
More details about the acquisition can be found in the press release issued by Thermo Fisher Scientific on March 31, 2016, which is included as Exhibit 99.1 to this 8-K filing.